F O R I M M E D I A T E R E L E A S E
Medtronic Introduces Paradigm® 712 Insulin Pump With Larger Reservoir
Larger Reservoir Helps Patients Who Require More Insulin; Pump Also Calculates Complex Diabetes Math and Recommends Insulin Dosage to Help Improve Patients' Health
NORTHRIDGE, Calif., Oct. 28, 2003 - Medtronic, Inc. (NYSE: MDT), today announced the market introduction of its Paradigm® 712 insulin pump, which incorporates a larger reservoir for diabetes patients requiring more insulin to keep their blood sugar levels within a normal range. The new pump, which was recently cleared by the U.S. Food and Drug Administration, is small, easy to use and can replace insulin shots for many people using insulin to treat diabetes. The Paradigm 712 pump's larger three-milliliter (3 ml) reservoir is well suited for children, young adults, insulin-resistant Type 1 and Type 2 patients, and women with gestational diabetes. The Paradigm 712 pump holds up to 300 units of insulin and is designed for patients who use more than 50 units of insulin per day. The pump's larger reservoir enhances patient convenience by enabling users to change their insulin reservoirs less often.
"This is an excellent tool to improve diabetes control in anyone requiring more daily insulin, particularly young children and teens whose bodies are still growing," said Francine R. Kaufman, M.D., head of the Center of Diabetes and Endocrinology at Childrens Hospital of Los Angeles, professor of pediatrics at the Keck School of Medicine of University of Southern California, and immediate past president of the American Diabetes Association. "This pump is also very smart. It simplifies diabetes management by providing insulin dosing support to patients, making it easier for them to deliver the correct amount of insulin to normalize and maintain blood sugar levels, which helps improve health and quality of life for many patients."
Paradigm 712 Insulin Pump System
Similar to the recently introduced Paradigm 512 pump system, the innovative Paradigm 712 system integrates blood sugar information using the Paradigm LinkTM Blood Glucose Monitor, co-developed with BD (Becton, Dickinson and Company) (NYSE: BDX). The Paradigm Link monitor automatically transmits a blood sugar value to the Paradigm 712 insulin pump using wireless communication. The "intelligent" pump then uses its built-in Bolus Wizard™ calculator to perform complex "diabetes math" and recommend a proper insulin dosage based upon information entered by the user. The pump also keeps track of insulin previously delivered by the patient and still active in the body, helping patients reduce common episodes of low blood sugar.
"Making pump therapy easier and more convenient plays a major role in improving diabetes control," said Jeffery A. McCaulley, vice president and general manager of Medtronic's Diabetes business. "Both our Paradigm 512 and 712 pumps provide enormous advantages to patients by automating the exchange of blood sugar values between the meter and the pump and recommending more accurate insulin doses to patients. As the insulin pump technology leader, we look forward to introducing a steady stream of innovative products to help improve health and extend life for diabetes patients."
It is estimated that more than 1 million Americans with Type 1 diabetes and another 3 million to 4 million with Type 2 diabetes use insulin to control blood sugar levels, improve their health and attain a better quality of life. High and low blood sugar fluctuations can cause loss of consciousness or even death, as well as long-term complications such as blindness, kidney failure, amputation, impotence and heart disease. For many patients, managing diabetes is difficult without the use of an insulin pump and frequent blood glucose monitoring.
An external insulin pump is a pager-sized, battery-operated device that can be worn on a patient's belt or hidden beneath a layer of clothing. It delivers fast-acting insulin from a reservoir inside the pump to the body through a tiny plastic tube, called an infusion set. Pump therapy more closely mimics the insulin delivery of a healthy pancreas. Unlike insulin shots, a pump automatically delivers a constant rate of insulin around the clock, and users can easily start and stop additional insulin delivery upon demand.
BD (www.bd.com) is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. The Paradigm Link monitor is powered by BD LogicTM Technology.
Medtronic MiniMed (www.minimed.com) is the world leader in insulin pump therapy and continuous glucose monitoring. The company's products include external insulin pumps, related disposable products, and a continuous glucose monitoring system. Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the world's leading medical technology company, providing lifelong solutions for people with chronic disease. Additional information about Paradigm 512 and 712 insulin pumps and the Paradigm Link monitor is available online at www.minimed.com.
- 0 -
EDITOR'S NOTE: Detailed information about diabetes, insulin pump therapy, the Paradigm 512 and 712 pumps and Paradigm Link Blood Glucose Monitor is available by accessing Medtronic's online newsroom at www.medtronic.com/newsroom.
Any statements made about the company's anticipated regulatory approvals are forward-looking statements subject to risks and uncertainties such as those described in the company's Annual Report on Form 10-K for the year ended April 25, 2003. Actual results may differ materially from anticipated results.
Last Updated: Tuesday October 28, 2003 16:02:14
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by Children With Diabetes, Inc, which is responsible for its contents.
© Children with Diabetes, Inc. 1995-2014. Comments and Feedback.